Joe Jimenez (Getty Images)

Joe Jimenez has one more thing to do in bio­phar­ma. And now he and Mark Fish­man have a $133M stake to play the start­up game

Big Phar­ma ex­ecs usu­al­ly don’t just fade away. Some­times, they jump to the mon­ey side of the biotech busi­ness, like Chris Viehbach­er and Olivi­er Brandi­court. Some stick with a batch of men­tor­ing board seats. Joe Jimenez not on­ly plans to do both, he’s al­so go­ing biotech en­tre­pre­neur and start­ing his own play — in style.

A week ago, Jimenez and his close part­ner Mark Fish­man, who got to know each oth­er well dur­ing their re­spec­tive time as CEO and ear­ly-stage NI­BR chief at No­var­tis, filed pa­pers with the SEC not­ing that their Adi­tum Bio Fund I had raised the $133,040,000 they had tar­get­ed more than a year ago.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.